Company Encyclopedia
View More
name
SIRIO
300791.SZ
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutritious gummies; probiotic balls; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging.
255.10 B
300791.SZMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
B
Personal Care ProductsIndustry
Industry Ranking8/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE13.60%B
    • Profit Margin7.76%B
    • Gross Margin31.02%C
  • Growth ScoreB
    • Revenue YoY7.90%B
    • Net Profit YoY2.93%C
    • Total Assets YoY11.24%B
    • Net Assets YoY6.85%B
  • Cash ScoreB
    • Cash Flow Margin1288.98%B
    • OCF YoY7.90%B
  • Operating ScoreB
    • Turnover0.8B
  • Debt ScoreC
    • Gearing Ratio53.22%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SIRIO released its performance for the first three quarters, with a net profit attributable to the parent company of 260 million yuan, an increase of 8.53%

    According to the Zhitong Finance APP, SIRIO released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 3.291 billion yuan, a year-on-year increase of 7.96%. The net profit attributable to shareholders of the listed company was 260 million yuan, a year-on-year increase of 8.53%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 244 million yuan, a year-on-year increase of 3.42%. The basic earnings per share were 0.8523 yuan

    Zhitong·
    SZ
    300791
    -1.32%
    Zhitong·
    SZ
    300791
    -1.32%

    Certain A-Shares of Sirio Pharma Company Limited are subject to a Lock-Up Agreement Ending on 25-SEP-2025.

    Certain A-Shares of Sirio Pharma Company Limited are under a Lock-Up Agreement until 25-SEP-2025, lasting 2193 days from 24-SEP-2019. Key shareholders, including Guangdong Guanghui Investment Co., Ltd. and others, have committed to not disposing of their shares for 36 months post-listing, while some shareholders have a 12-month restriction. After the lock-up period, annual share transfers will be limited to 25% of their holdings.

    marketscreener·
    SZ
    300791
    -1.32%
    marketscreener·
    SZ
    300791
    -1.32%

    Guangfa Securities: Consumer goods consumers pursue "cost-effectiveness + high value" and are optimistic about the recovery of demand after the clearance of liquor

    Guangfa Securities released a research report indicating that the consumer goods industry is undergoing channel transformation, with consumers pursuing "cost-effectiveness + high value." Companies need to pay attention to demands for cost-effectiveness, health, convenience, etc., and leading enterprises with strong product power will benefit. After adjustments, the liquor industry is expected to see a recovery in demand by 2025. Snack and chain food companies are facing differentiation and profitability pressures, and new changes and business expansion need to be monitored

    Zhitong·
    SZ
    300783
    -1.43%
    SZ
    002946
    -0.95%
    HK
    02517
    -2.54%
    Zhitong·
    SZ
    300783
    -1.43%
    SZ
    002946
    -0.95%
    HK
    02517
    -2.54%

    HuaChuang Securities: Functional foods accelerate penetration, tapping into new opportunities in industry reshaping

    Huachuang Securities released a research report indicating that China's functional food industry has maintained a compound annual growth rate of 6.3% over the past five years, significantly higher than other consumer goods categories. Economic stability, aging population, and the rise of Generation Z are driving the accelerated penetration of functional foods, with consumer groups including women, teenagers, infants, and pets. Online channels such as Douyin and cross-border e-commerce are experiencing rapid growth, and the industry landscape shows a coexistence of leading companies and long-tail players. It is recommended to pay attention to companies like SIRIO and Biohigh

    Zhitong·
    SH
    603102
    +0.81%
    SZ
    300791
    -1.32%
    Zhitong·
    SH
    603102
    +0.81%
    SZ
    300791
    -1.32%

    SIRIO released its performance for the first half of the year, with a net profit attributable to the parent company of 161 million yuan, a year-on-year increase of 4.30%

    According to the Zhitong Finance APP, SIRIO released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 2.042 billion yuan, a year-on-year increase of 2.57%. The net profit attributable to shareholders of the listed company was 161 million yuan, a year-on-year increase of 4.30%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 159 million yuan, a year-on-year increase of 3.25%. The basic earnings per share were 0.5276 yuan

    Zhitong·
    SZ
    300791
    -1.32%
    Zhitong·
    SZ
    300791
    -1.32%
    © 2025 Longbridge｜Disclaimer